News

ABSTRACTBackground and AimsHereditary transthyretin amyloidosis (ATTRv) is a multisystemic disease where early neuropathy signs are challenging to detect…

AbstractThe management of transthyretin amyloid cardiomyopathy (ATTR-CM) has revolved around the scintigraphic diagnosis since the introduction of a specific…

The safety and efficacy of vutrisiran are consistent with those observed in the overall population of East Asian patients treated in the phase 3 clinical trial…

Two Al algorithms from Anumana received FDA (US Food and Drug Administration) clearance in early2026 for something a standard 12-lead ECG has never been validated…

'Golden Years': Changing the story of ATTR-CMATTR-cardiac amyloidosis (ATTR-CM) is a progressive heart condition often mistaken for normal aging. For years,…

Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, announced…

Study OverviewBrief SummarySystemic light chain amyloidosis (AL amyloidosis) is the most common type of systemic amyloidosis, with diverse clinical manifestations…

The U.S. Food and Drug Administration approved Attruby (acoramidis) for adults with cardiomyopathy of wild-type or variant (hereditary) transthyretin-mediated…

AccurKardia said it was granted a U.S. patent for its machine-learning-based algorithm that can identify cardiac amyloidosis from a standard 12-lead ECG. Use of ECG…

In people with transthyretin amyloid cardiomyopathy (ATTR-CM), the buildup of faulty transthyretin (TTR) protein in the heart may contribute to blood clots that…